FP03.02 Interim Analysis of Neoadjuvant Chemoradiotherapy and Durvalumab for Potentially Resectable Stage III Non-Small Cell Lung Cancer (NSCLC)
Min Hee Hong, Beung‐Chul Ahn, H.R. Kim, Sungsu Lim, S. Lee, S.Y. Park, C.Y. Lee, J.G. Lee, D.J. Kim, Sun Hee Lee, H.I. Yoon, C.G. Lee, Junho Cho, Hyo Sup Shim, Tae‐Yoon Kim, B.C. Cho
Topics & Concepts
DurvalumabMedicineOncologyInterim analysisChemoradiotherapyInterimStage (stratigraphy)Internal medicineNeoadjuvant therapyLung cancerCancerClinical trialImmunotherapyNivolumabPaleontologyHistoryBiologyBreast cancerArchaeologyLung Cancer Treatments and MutationsCancer Immunotherapy and BiomarkersGastric Cancer Management and Outcomes